Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 4/20 | 0.36 |
| ▸ | CASP2 | P42575 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7870212 | 0.93 | EPHX1 (0.62) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL28375139 | 0.91 | EPHX1 (0.66) | EPHX1CA2CA1CA7CNR1 | |
| SCHEMBL28379256 | 0.91 | EPHX1 (0.66) | EPHX1CA2CA1CA7CNR1 | |
| SCHEMBL6435794 | 0.86 | EPHX1 (0.52) | EPHX1CA2CA1CA7CA13 | |
| Hydrochloric Acid SCHEMBL927607 | 0.84 | EPHX1 (0.50) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL9951303 | 0.83 | EPHX1 (0.47) | EPHX1CA2CA1CNR1CNR2 | |
| SCHEMBL12789664 | 0.80 | EPHX1 (0.60) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL15904262 | 0.79 | EPHX1 (0.61) | EPHX1CA2CA1CA7CA13 | |
| SCHEMBL6435515 | 0.78 | ALDH1A1 (0.56) | CA2CA1MEN1KMT2AHTT | |
| SCHEMBL6433489 | 0.77 | CA2 (0.39) | EPHX1CA2CA1CA7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-6323174-B1 | PERFUME COMPOSITION AT LEAST COMPRISING 4-METHYL-5-HEXEN-1-AL | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-27 | — | — | US | disclosed |
| US-6239324-B1 | REACTING A 1,3-BUTADIENE WITH OLEFIN IN PRESENCE OF HYDROPHILIC SOLVENT AND RUTHENIUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | EPHX1 1247/4885CA2 4372/4885CA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.